Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary ...

Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

Patients were treated with a genetically modified HSV-1 in combination with an immunotherapy (nivolumab). By the end of the ...

Nivolumab, a fully human immunoglobulin G4 anti–PD-1 immune checkpoint inhibitor monoclonal antibody, has demonstrated frequent and durable responses with a favorable safety profile as monotherapy in ...

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved ...

EFS rate at 18 months was also 20 percentage points higher among the patients who received nivolumab vs placebo (70% vs 50%), and more of the patients randomized to treatment with nivolumab plus ...

Nivolumab-based combinations may therefore "offer clinicians and payers a therapeutic option for previously untreated advanced RCC that may reduce the substantial clinical and economic impacts in ...